All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The U.S. NIH’s National Institute on Aging’s Intervention Testing Program has been searching for ways to extend lifespan for more than two decades by now. And in its animal studies, it has been successful multiple times. There are half a dozen drugs, and a few lifestyle interventions, that reliably extend lifespan in one or both sexes by up to 30%. Read more in part four and five of BioWorld’s multipart series on extending the human lifespan.
Remarkably, the U.S. NIH’s National Institute on Aging’s Intervention Testing Program (ITP) has achieved its success rate while keeping to the highest standards of scientific rigor. Any researcher can suggest drugs that the ITP might test. The program can only test a fraction of the suggestions in gets, though, so proposals go through a rigorous vetting process.
A lot of what goes on during aging remains too poorly understood for straightforward translation. There are hallmarks of aging, and researchers are getting a handle on its biological mechanisms. But in a basic sense, “we still don’t have much of an idea what causes aging,” said Björn van Eyss of the Leibniz Institute for Aging Research. Part six of BioWorld’s multipart series on extending the human lifespan explores the moonshot attracting the most attention: in vivo partial reprogramming.
In the biopharma industry, the sirtuins have been a cautionary tale of some of the challenges in translating aging research. Research in the early aughts suggested that activating them could extend lifespan, and the spectacular rise of sirtuin activators crested in 2008, when GSK plc bought preclinical startup Sirtris Pharmaceuticals Inc. to the tune of $720 million, only to shutter it a few years later. But the hopes attached to sirtuin activators have not panned out. Read more in part seven of BioWorld’s multipart series on extending the human lifespan.
If anti-aging drugs are to become widely available and adopted, especially in the U.S., they have some serious hurdles to overcome. And those hurdles aren’t all in the lab or clinic. With classes of anti-aging drugs already in the pipeline, “the biggest hurdle is FDA approval. Then reimbursement,” said George Kuchel, a professor and director of the UConn Center on Aging at the University of Connecticut. Read the final installment of BioWorld’s multipart series on extending the human lifespan.
The mosaic loss of Y chromosome in myeloid cells is a major risk factor for increased incidence of cardiovascular and fibrotic diseases during aging. The authors of a study published in the July 14, 2022, online edition of Science found that bone marrow-derived myeloid cells exhibited mLOY during aging.
Using long-term in vivo imaging combined with computational modeling, a multinational team of researchers has gained new insights into what makes potential stem cells able to fulfill their role functionally.
Researchers have discovered how the tau protein turns from a normal to a disease state in Alzheimer's disease (AD) and have shown how the discovery could potentially deliver a therapeutic target.
Several genetic studies in a range of model organisms have pointed to an important role for the B-cell lymphoma 2 (BCL2)-associated athanogene 3 (BAG3) gene in the maintenance of cardiac function.
RSS
